N2B

Treatment of Parkinson’s-related Depression

Company Name
Updating Date
Neurotech Category
Market Category
Target Market
Technologies
Company Founded Year
Company Number of Employees
N2B
Biotechnology & Biopharmaceutical
01/01/2015
"1-10"
Go to company site

N2B Ltd is developing an intranasal delivery formulation of the approved drug Rasagiline for the treatment of depression associated with Parkinson’s disease (PD). The company is on a quick regulatory pathway for NDA submission through the U.S. FDA 5O5(b)(2) approach.



N2B’s preclinical results indicate that intranasal delivery of Rasagiline could provide both a useful alternative to oral administration in the treatment of PD and a novel therapeutic approach for the treatment of depression in PD patients.



N2B was founded as an incubator company of Youdim Pharmaceuticals.